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CHAPTER 1: GENERAL INTRODUCTION 
 
Introduction 
Swine influenza A virus (IAV) is an economically important disease with zoonotic 
potential. In the United States, six H1 antigenic clusters (α, β, γ, δ-1, δ-2, and pandemic) 
currently circulate in swine. Continual evolution of surface genes in the virus by point 
mutations (antigenic drift) and genetic reassortments with other circulating viruses (antigenic 
shift) contributes to the diversity of IAV in swine. In addition, introduction of human IAV 
into swine has contributed to the pool of IAV circulating in swine [1-4] 
Current vaccine strategies for IAV in swine provide limited cross-protection due to 
antigenic variation in circulating virus; however, more recently developed live-attenuated 
influenza virus (LAIV) vaccines are more efficacious in protection against swine IAV. LAIV 
vaccination provides better protection against homologous and heterologous viruses as 
compared to whole-inactivated virus (WIV) vaccines [5, 6]. LAIV vaccination is available 
for human use, however, it is not yet an approved intervention for swine IAV.  
The objective of this thesis was to evaluate different assays that measure IFN-γ in 
antigen-specific recall assays as it relates to IAV vaccines for swine. The IFN-γ assays used 
were a proxy of IAV-specific cell-mediated immunity elicited following IAV vaccination. 
Cell-mediated immunity (CMI) following vaccination was measured as the ability of 
peripheral blood mononuclear cells (PBMC) to produce IFN-γ in response to in vitro antigen 
re-stimulation. IFN-γ is a pro-inflammatory Th1 cytokine, which has been shown to play a 
role in vaccine efficacy[7]. The accepted correlate of protection for IAV is antibody to viral 
surface glycoprotein. However, several studies have indicated that the antibody response is 
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not always related to cross-protection when subjects are administered LAIV vaccine and 
instead, cell-mediated immunity may be a better gauge of LAIV immunogenicity and cross-
protection. Various immune assays are available for measuring antigen-specific IFN-γ 
responses, such as ELISpot and ELISA, but these assays may give different results and 
subsequently alter interpretations of vaccine elicited CMI. Thus, understanding the 
relationship between different assays used to evaluate antigen-specific IFN-γ responses will 
be useful for understanding vaccine immunogenicity.   
In order to assess antigen-specific IFN-γ responses, as a single measure of cell-
mediated immunity following vaccination, IAV-specific IFN-γ responses were measured in 
both ELISpot and ELISA assays using samples from WIV and LAIV vaccinated pigs. 
Peripheral blood mononuclear cells (PBMC) were used to determine expression of IFN-γ 
after ex vivo stimulation with live virus in both ELISpot and ELISA assays. Additionally, the 
effect of age at the time of WIV vaccination and vaccine formulation (i.e. adjuvant) were 
assessed using both assays.  
Thesis Organization 
This thesis is organized into three chapters. The first chapter presents a general 
overview of IAV in swine and a brief review of the epidemiology of swine IAV, virus origin 
and classification, vaccination and vaccine platforms, antibody-mediated immunity, cell-
mediated immunity, and IFN-γ specific assays used for assessing cell-mediated immune 
responses. The second chapter presents results detailing differential measures of cellular IFN-
γ responses in swine following vaccination. The final chapter summarizes the research results 
and provides suggestions for future research in this area. 
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Literature Review 
Epidemiology of swine influenza 
IAV causes respiratory disease in swine and contributes to the Porcine Respiratory 
Disease Complex. Swine IAV infection is characterized by fever, lethargy, sneezing, 
coughing, dyspnea, and appetite suppression. In addition to causing primary disease, IAV can 
predispose pigs and other host species to secondary bacterial infections [8-10].  
In swine there is a high morbidity rate associated with IAV infection, but there is not 
a significant mortality rate reported. Sows can be more heavily impacted during gestation or 
when farrowing. An observed increase in abortions, stillbirth rates, slow farrowings or 
premature farrowings may occur within sow herds during an influenza outbreak, though, 
these events may be under reported in the field  (reviewed in [11]). Despite the low mortality 
rates reported, IAV remains as an economically impactful respiratory disease in swine [2, 
12].  
A factor contributing to the impact of IAV in swine is its potential for zoonosis with 
spillover into the human population[2], or spillover into the swine population. Seasonal IAV 
in humans is responsible for 3-5 million cases of severe influenza and about 250,000-500,000 
deaths worldwide annually as reported by WHO (reviewed in [13]). The incidence of IAV in 
humans leaves opportunity for spillover into the swine population, several cases have been 
recently documented in Brazil and Germany, which can contribute to the diversity of 
circulating reassortants [3, 4, 14].  In addition, IAV from swine can spillover to human, 
which has typically been associated with close interaction between pigs and people at 
agricultural fairs. 
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Virus origin and classification 
IAV is a negative-sense, single-stranded RNA virus, belonging to the family of 
Orthomyxoviridae. Its genome consists of eight gene segments, HA, NA, PB1, PB2, PA, NP, 
NS and M, that encode 10 or 11 viral proteins.  IAV is classified by the surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA). There are three IAV subtypes 
that predominantly affect pigs worldwide: H1N1, H1N2, and H3N2 [1, 2], although, other 
IAV subtypes, such as H3N1 viruses [15, 16] have circulated within swine populations [1].  
Influenza disease in swine was first recognized in 1918 in the Midwestern U.S. 
during the Spanish influenza pandemic in humans[17]. It was subsequently isolated in 1930 
from pigs in the U.S. The 1930 swine IAV strain is classified as classical H1N1 virus 
(cH1N1). For nearly 80 years following the first isolation of IAV in swine, IAV was 
relatively stable both genetically and antigenically as it circulated in swine in the U.S. 
(reviewed in [1]). 
In 1998, the epidemiology of IAV in U.S. swine changed when triple-reassortant 
H3N2 viruses were first isolated from pigs. These viruses contained gene segments from the 
classical swine virus (NP, M, and NS), H3N2 human seasonal IAV (PB1, HA, NA) and avian 
IAV (PB2, PA) [1]. This constellation of genes is referred to as the triple-reassortant internal 
gene (TRIG) cassette [1]. Regardless of HA and NA subtype, most characterized swine 
viruses contain the TRIG cassette [18]. Swine also have the ability to infect other species, 
such as turkeys which can be infected by the TRIG-containing swine viruses circulating in 
North America [19], this transmission of virus to other species may have implications on 
swine health because of reassortment events that may occur. Additionally pigs play an 
important role in transmission of novel viruses to humans by acting as a ‘mixing vessel’ [20-
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22]. Since the introduction into swine, H3N2 viruses have evolved and are currently endemic 
in swine herds in North America.  
The reassortment between triple-reassortant H3N2 virus and the cH1N1 virus gave 
rise to H1N2 viruses that contain the HA from cH1N1 and the NA and internal genes from 
the triple reassortant H3N2 viruses [2]. H1N1 and H1N2 viruses with either HA, NA or both 
derived from human seasonal IAV began emerging in 2005.  These viruses spread through 
U.S.  swine herds and are currently endemic [23]. 
In 2009, a H1N1 virus containing internal genes closely resembling that of IAV 
circulating in swine emerged in humans. The virus was classified as swine-origin IAV 
because of a unique genome consisting of six RNA gene segments (PB2, PB1, PA, HA, NP 
and NS) that were genetically similar to those in viruses circulating in North American swine 
herds[24, 25], and the other two gene segments (NA and M were related) were most closely 
related to IAV in Eurasian swine.  
A classification scheme based on phylogenetic clusters of the H1 gene was 
established for North American swine IAV to discern the evolution and classify H1 IAV 
[23]. Evolution of the HA gene of cH1N1 viruses circulating in swine since 1918 gave rise to 
three distinct phylogenetic clusters (α, β, and γ-clusters). A fourth cluster, the δ-cluster, has a 
HA gene most similar to that of human seasonal H1 viruses which have circulated since the 
early 2000s. This δ-cluster contains branches into two distinct clusters, δ-1 and δ-2, which 
are differentiated by two separate introductions of human seasonal IAV into swine. The virus 
that emerged globally in 2009 is referred to as the pandemic cluster, and is most closely 
related to the HA in classical swine IAV. Viruses with each HA gene cluster type have been 
isolated with NA genes of either the N1 or N2 subtype [1, 3, 4].  
6 
 
Vaccination and vaccine platforms 
Vaccination can be an effective means for prevention and control of IAV. Prior to the 
licensing of a new replicon particle vaccine [26], only whole-inactivated virus (WIV) 
vaccines were commercially available to control IAV in swine (reviewed in [2, 27]). WIV 
vaccines are administered via intramuscular injection, and in conjunction with an adjuvant to 
increase the immunogenicity. WIV vaccines generally are formulated with H3 and H1 
subtypes, and they may contain multiple viruses of each subtype [28].   
Swine IAV vaccines are formulated with adjuvants which can have benefits, such as 
enhancing antibody responses in situations where the WIV alone is poorly immunogenic or 
in cases when mass quantities of vaccine antigen is needed for a naïve population[29, 30]. 
Adjuvants can activate the innate immune system which has been shown to enhance both 
antibody and cell-mediated adaptive immune responses. Data indicates adjuvanted vaccines 
can elicit stronger, more persistent and broader immune response against H3N2 strains than 
non-adjuvanted IAV vaccines[31]. Intramuscular delivered WIV vaccines have been shown 
to induce immune responses readily measurable in peripheral blood. Most commonly this 
measurement is based upon the serum antibody response, typically measured in a 
hemagglutination inhibition (HI) assay. Serum HI antibody titers are the most commonly 
measured correlate of protection for IAV. Historically, measurement of antibody responses 
following vaccination has been utilized to predict a protective response. A HI titer of equal to 
or greater than 1:40 has been used as benchmark of protective serum antibody response when 
evaluating vaccination or challenge[32]. 
While WIV vaccines for IAV can induce an immune response that plays a role in 
disease prevention and potentially reduce viral shedding, WIV based vaccines have several 
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drawbacks. For instance, production of WIV vaccines are time sensitive such that antigenic 
changes in IAV can progress faster than traditional vaccines can be developed, thus limiting 
the efficacy against current circulating IAV. Also, there is limited efficacy against 
heterologous homosubtypic or heterosubtypic viruses [33].  Further, there is potential for 
vaccine/challenge mismatch that in some cases can result in vaccine enhanced associated 
respiratory disease (VAERD) [12, 33]. 
Live-attenuated influenza virus (LAIV) vaccination has been shown to induce a 
secretory and systemic immune response that more closely mimics natural infection [34]. 
LAIV vaccines have been developed by inducing mutations into the viral genome to render 
the virus attenuated. For example, a temperature-sensitive (ts) LAIV  has been engineered by 
introducing point mutations in the polymerase genes that decrease the viruses ability to 
replicate in the warmer lower respiratory tract [35]. Initially, this LAIV was created with the 
use of reverse genetics with a swine-like triple-reasssortant virus, A/turkey/Ohio/313053/04 
(H3N2) [36]. Due to the genetically modified backbone, the polymerase activity is impaired 
rendering viral growth at elevated temperatures limited [35]. This LAIV was initially 
developed with pandemic surface genes (HA and NA), but has also been rescued with other 
surface genes, including the HA and NA of a δ-cluster virus [37, 38]. LAIV vaccines that 
contain the genes encoding the surface glycoproteins (HA and NA) of a wild-type virus and 
six internal gene segments from the attenuated donor strain (PB1, PB2, PA, M, NP, and NS) 
are referred to as 2+6 reassortants [34]. 
Several studies have shown that LAIV vaccines induce immune responses in pigs that 
provide a degree of protection against both homologous and heterologous challenge, and 
LAIV vaccines are more efficacious in this regard than other vaccine platforms[5, 27, 38, 
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39]. Furthermore, in swine, tsLAIV has been shown to be immunogenic with the ability to 
provide sterilizing immunity to homologous pandemic H1N1 virus challenge, and protect 
against heterologous challenge [37, 38]. 
The immune status of young pigs more closely resembles that of children as far as 
age and prior vaccination status. Immune status plays an important role in the serologic 
response to IAV vaccination, and children have been shown to elicit antibody responses 
following LAIV vaccination. Also, the induction of IAV-specific T cells following LAIV 
vaccination appears to be more prominent in children [40, 41]. LAIV has also been shown to 
induce a broader memory response [27], which in terms of vaccination is essential. Vaccines 
that are aimed at inducing a productive CD4+ T cell response induce multiple subsets of T 
cell memory [42]. Since LAIV vaccine platform undergoes limited replication, it is likely 
that LAIV acts in a similar manner as natural infection allowing appropriate memory T cell 
subsets to be established, unlike WIV vaccines [42].  
Standard IAV vaccination is largely aimed at stimulating the production of 
neutralizing antibodies against HA and NA, which bind the virus and prevents entry into host 
cells [43]. But for LAIV, it has been suggested that other aspects of the immune response 
may correlate better to protection, such as cell-mediated responses. LAIV has many 
promising factors that make it superior to WIV vaccination, however, is limited when 
determining what immune measures could be used as a correlate of immunogenicity and 
protection to predict protection upon homologous or heterologous challenge. 
Antibody-mediated Immunity 
Antibodies targeting the viral surface glycoproteins, HA and NA, play a prominent 
role in protection against disease. HA is responsible for the attachment of the virus to sialic 
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acid-containing receptors on the host cell surface.  HA is also responsible for the fusion 
between viral and endosomal membranes resulting in release of ribonucleotide NP (RNP) 
into the cytoplasm. The HA head has the receptor-binding site at the tip of each monomer 
containing five antigenic sites, which neutralizing antibodies are capable of binding and 
preventing subsequent infection [34].The NA cleaves sialic acid and plays an important role 
in viral release [34]. The NA consists of a hydrophobic stalk and a globular head that 
contains enzymatic and antigenic sites. IAV is constantly undergoing antigenic shift and drift 
to evade the host’s adaptive immunity, thus increasing evasion from antibody-mediated 
immune response.   
Antibody-mediated immunity has historically been used as a measure of protective 
immune responses [44] against IAV. IAV vaccination aims to induce HA-specific 
neutralizing antibodies, the primary mechanism known to provide sterilizing immunity 
against IAV infection [34]. While antibody mediated protection may be effective against 
homologous strains of IAV, it provides little to no protection against most heterologous 
strains with drifted surface proteins. The presence of cross-reactive but non-neutralizing 
antibodies has been associated with enhancement of disease (implicated in VAERD) upon 
heterologous challenge as well. Newer vaccine platforms, including LAIV, can induce a poor 
peripheral antibody response. Thus, while LAIV is protective against heterologous challenge 
peripheral antibody responses are not a good measure of predicting cross-protection. [45]. 
In addition to serum antibody, secretory immunoglobulin A (sIgA) and IgM specific 
to IAV can be major neutralizing antibodies (NAbs). NAbs  have been shown to be directed 
towards mucosal pathogens, such as IAV [34]. NAbs can prevent pathogen entry by binding 
receptor binding domains on the virus surface glycoprotein and blocking attachment to the 
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host cell. Secretory IgA is involved in protection of the upper respiratory tract and peripheral 
IgG in the lower respiratory tract[34]. Due to the polymeric nature, IgA is believed to be 
more cross-reactive when compared to monomeric IgG [46].   
Antigen-specific serum antibody titers are often used to evaluate vaccine 
immunogenicity. However, these data are not always sufficient in predicting the outcome 
after infection, such as a positive or negative outcome for the vaccinated animal as it relates 
to the potential development of VAERD. Additionally, following LAIV vaccination the 
detection of serum antibodies is limited, thus measuring an effective immune response with 
serum antibody is not an advantageous way to predict a protective immune response.   
Cell-mediated immunity 
Influenza-specific T cells have been shown to be protective in animal models, 
specifically the contribution of CD4+ T cells that provide secondary signals for induction of 
antibody responses. CD4+ T cells facilitate B cell activation which leads to differentiation 
and antibody production. They can also influence isotype switching to generate protective 
neutralizing antibodies.  
During IAV infection T cells can produce antiviral and proinflammatory cytokines, 
such as IFN-γ, IL-2, and TNF-alpha can directly help recruit other immune cells to assist 
with viral clearance [43]. CD4+ provide help to CD8+ T cells via cytokine production, which 
enables optimal CD8+ memory T cell differentiation. CD4+ T cells can also induce 
production of various innate inflammatory cytokines and chemokines from other cells, as 
well as secreting cytokines themselves to recruit innate immune cells to the site of infection 
[43]. Thus these factors can help drive proper clearance and protection against IAV. In 
addition, CD8+ T cells are capable of eliminating virus infected cells through effector 
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mechanisms. T cells may play a role in limiting disease severity [13], including mitigating 
virus shedding.  
Th1 cells primarily produce the proinflammatory cytokine IFN-γ, and are required for 
clearance of intracellular pathogens[7]. Despite IFN-γ playing a protective role in clearance 
of some infection, the response must be properly regulated to avoid severe tissue injury and 
even host death [43, 47].  IFN-γ can be produced by both T effector and T memory cells. In 
swine, memory T cells are characterized by expression of both CD4 and CD8α, which are 
referred to as CD4/CD8 double-positive (DP) T cells. This population of cells has the ability 
to expand in response to recall antigen and produce IFN-γ [48]. However, they may not be 
the only memory T cell population. 
Influenza-specific T cells can recognize epitopes from internal IAV influenza 
proteins, which are quite conserved across IAV strains [43]. Thus, stimulating robust 
induction of memory T cell responses specific to internal viral proteins with vaccination is 
appealing because it can offer broader protection than current vaccines that drive antibody-
based protection against viral surface glycoproteins. The cytotoxic T lymphocyte (CTL) 
response has been shown to be cross-reactive between IAV strains and can help to mitigate 
disease in combination with antibody [34]. Human studies have confirmed that in the absence 
of protective antibodies to the homologous virus strain, CTL responses can play a role in 
recovery from an influenza infection. The CTL response is directed against M and NP 
proteins and although this does not confer complete protection against IAV infection, it does 
serve a role in viral clearance and recovery. Additionally, M and NP have less variation than 
HA and NA [43]. 
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T cell assays for assessing cell-mediated responses 
Production of IFN-γ by T cells after antigen restimulation has been utilized as one 
quantitative marker of cell-mediated immunity over the past few decades as noted by Thakur 
et. al.[7].  Various assays have been developed to measure IFN-γ in various recall assays and 
subsequently make inferences on the induction of CMI in response to vaccination or 
infection. This includes, but is not limited to, IFN-γ specific ELISA and ELISpot.  
The enzyme-linked immunosorbent assay (ELISA) can be used to quantify cytokines 
secreted by lymphocytes after antigen-stimulation in vitro. The ELISA is useful for cytokine 
detection because large numbers of samples can be collected, frozen for storage and tested 
when time permits. The drawbacks of an ELISA may include inability to phenotype the cell 
population producing a cytokine and failure to determine the frequency of cells that express 
the cytokine. Also, detection of cytokine protein by ELISA does not ensure that the protein is 
biologically active. Assay sensitivity is limited and cytokines expressed at low levels may be 
difficult or impossible to detect [45]. 
The enzyme-linked immunospot (ELISpot) assay can be used to quantify the number 
of cells secreting a particular cytokine in response to antigen restimulation using an ELISA 
based format. Cytokine-specific antibody captures cytokine as it is produced by cultured 
cells.  One or 2 days after in vitro antigen stimulation, cells are removed and secreted 
cytokine is detected, resulting in spot formation on the membrane of the individual culture 
well. The number of spots are enumerated and recorded as the number of cells producing the 
cytokine. The ELISpot assay is very sensitive with detection of less than 0.01% Ag-specific 
T cells [49]. The amount of cytokine produced can be deduced by simultaneous measurement 
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of spot size, but is not frequently evaluated. As with ELISA, a drawback of ELISpot analysis 
includes lack of phenotype data for cells producing a particular analyte, though methods have 
been used to overcome these drawbacks. This includes measuring spot size and sorting 
specific cell populations to evaluate in the ELISpot, respectively.  
Antigen-specific cytokine-producing cells are often present at low frequencies, 
making assay sensitivity a potential problem for both assay platforms. However, both assays 
can provide useful information on vaccine immunogenicity. Most vaccine studies measure 
cytokine secretion by T cells following antigen re-stimulation in vitro as a single measure of 
CMI induction [7]. However, it should be noted that IFN-γ may not be produced only by 
classic α/β T cells, as IFN-γ can be secreted by non-cytotoxic cells of both the innate and 
adaptive immune system. To clearly identify cells producing IFN-γ, cells can be sorted and 
phenotype can be determined prior to performing these assays.  
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Abstract 
Live-attenuated influenza virus (LAIV) vaccines provide broader cross-protection than 
whole-inactivated virus (WIV) vaccines against influenza A virus (IAV) in swine.  However, 
standard correlates of protection, such as serum hemagglutination inhibition (HI) antibody titers, 
do not accurately predict cross-protective efficacy provided by LAIV vaccines. While the 
contribution of T cells to IAV immunity is appreciated, data comparing methods to evaluate 
IFN-γ production by IAV-specific T cells is limited. To understand the differential 
immunogenicity between LAIV and WIV vaccines as it relates to induction of T cell responses, 
IFN-γ production by peripheral T cells following antigen restimulation was assessed post-
vaccination. ELISpot assays used to enumerate IAV-specific IFN-γ secreting cells (SC) in 
peripheral blood 42 days post-vaccination (dpv) indicated that WIV-vaccinated pigs had a 
greater number of IFN-γ SC compared to LAIV vaccinated pigs, regardless of recall IAV used. 
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In LAIV vaccinates there was no change in the number of IFN-γ SC to homologous IAV when 
comparing responses at  77 dpv to  42 dpv, but a decrease over time in WIV vaccinates. Pig age 
at time of WIV vaccination significantly effected peripheral IAV-specific IFN-γ recall responses. 
In only one instance were statistical differences between vaccine groups different between the 
ELISpot and ELISA, in all other cases, the same conclusion was made in regards to responses. 
Collectively, these data indicate that peripheral IAV-specific IFN-γ recall responses are not 
predictive of LAIV vaccination status, nor a useful surrogate for predicting cross-protection. 
However, the evaluation of IFN-γ recall responses may be useful for investigating factors, such 
as animal age or vaccine formulation that can affect immune responses to WIV vaccination.  
Introduction 
Influenza A virus (IAV) is a prevalent respiratory disease in swine and infection is 
characterized by fever, lethargy, sneezing, coughing, dyspnea, and appetite suppression. In 
addition to causing primary disease in swine, it predisposes swine to secondary diseases, such as 
bacterial infections[8]. Swine IAV can be zoonotic with noted spillover events to humans and 
poultry [19-21]. Currently in the United States three IAV subtypes predominantly circulate 
within the swine population, H1N1, H1N2, and H3N2. A phylogenetic classification scheme was 
established for swine IAV to discern the evolution and classify IAV [23]. Based upon this 
classification, there are six identified H1 antigenic clusters (α, β, γ, δ-1, δ-2 and pandemic) 
circulating in the North American swine population. The large diversity is due to constant 
evolution of the surface glycoproteins by both point mutations (antigenic drift) and genetic 
reassortments with other circulating viruses (antigenic shift). In addition, introduction of human 
seasonal IAV into swine, which can become endemic, also contributes significantly to the 
diversity of IAV in the US swine population. 
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Vaccination can be an effective means to prevent and control of disease, however, 
protection against IAV in swine is complicated by the number of antigenically distinct strains in 
circulation. The majority of currently available vaccines contain whole-inactivated virus (WIV) 
formulated with adjuvant for intramuscular administration. However, WIV vaccines provide 
limited cross-protection against diverse IAV. Newer vaccine platforms, such as live-attenuated 
influenza virus (LAIV), can be more effective in providing cross-protection when compared to 
WIV vaccination [5, 6]. While mucosal antibody likely contributes to the cross-protection 
associated with LAIV vaccination, the induction of cell-mediated immunity (CMI), particularly 
as an indicator of LAIV immunogenicity, has not been extensively explored, particularly in non-
rodent species.  
To evaluate differential immunogenicity of the WIV and LAIV platforms in swine as it 
relates to CMI, production of IFN-γ by peripheral IAV-specific cells was assessed in two 
different commonly used IFN-γ based assays (ELISA and ELISpot). IFN-γ is considered a 
canonical cytokine of the Th1 response and plays a crucial role in the vaccine-induced protection 
against several infections, including IAV [7, 50]. Thus, the primary goals of this work were to 
first, assess the induction of peripheral CMI, measured as IAV-specific IFN-γ production, in 
swine following vaccination with WIV or LAIV. The recall antigens used to measure the IFN-γ 
response following vaccination, included homologous virus which had matched surface genes to 
the vaccine strain, heterologous virus which had unmatched surface genes, but is of the same 
subtype to the vaccine strain, and heterosubtypic virus which had surface genes of a different 
subtype. Second, we compared IAV-specific IFN-γ responses by two different assays to 
determine if assay type altered our conclusions. Additional factors that may impact 
immunogenicity, including adjuvant and age at vaccination, were also assessed. Overall, our data 
17 
 
show that LAIV induces a very poor peripheral CMI response following vaccination and that 
responses to WIV vaccination are effected by both animal age at vaccination and adjuvant. These 
conclusions could be made regardless of the IFN-γ assay platform used.   
Materials and Methods 
Experimental animals and vaccine 
Three-week-old cross-bred pigs were obtained from a high-health status herd known to 
be free of influenza (IAV) and porcine reproductive and respiratory syndrome virus (PRRSV). 
Sera from pigs were tested by a commercial ELISA kit (MultiS ELISA, IDDEX, Westbrook, 
ME) to confirm that they were free of IAV-specific antibodies at the start of the experiment. 
Upon delivery to the facility, pigs were given ceftiofur crystalline-free acid (Zoetis Animal 
Health, New York, NY) and enrofloxacin (Bayer Animal Health, Shawnee Mission, KS). Pigs 
were housed in biosafety level 2 facilities and cared for in compliance with the Institutional 
Animal Care and Use Committee of the National Animal Disease Center.  
For both experiments described, pigs were vaccinated with whole-inactivated virus 
(WIV), live-attenuated influenza virus (LAIV) or remained non-vaccinated (NV). The WIV 
vaccine antigen contained A/SW/MN/02011/08 (MN08) virus propagated in Madin Darby 
Kidney (MDCK) cells. After approximately 80% cytopathic effect (CPE) was reached, the virus 
flask was frozen. One freeze/thaw was completed prior to collection of virus supernatant. 
Infected cultures were then utlracentrifuged (2 h at 140,000g through a 25% sucrose cushion) to 
pellet virus  After centrifugation the virus was resuspended in phosphate-buffered saline (PBS), 
diluted to 256 hemagglutination units (HAU) and then irradiated using the “sterilize” setting on a 
ultraviolet cross-linking chamber (GS Gene Linker; Bio-Rad, Hercules, CA). Vaccine virus was 
then frozen at -80 until day of vaccination. Two blind serial passages on MDCK cells were 
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performed on vaccine virus to confirm inactivation of the virus. Immediately prior to 
immunization, the WIV was formulated to 128 (HAU), mixed with a commercial adjuvant 
(Emulsigen D; MVP Laboratories, Inc., Ralston, NE) at a 1:5 ratio (v/v) for a final 2 mL dose per 
pig. The LAIV was generated as previously described [35]. Briefly reverse-genetics was used to 
rescue a virus with internal genes from A/turkey/Ohio/313053/04 (OH04, H3N2) with mutations 
introduced in the polymerase genes to render the virus temperature-sensitive [35] and surface 
genes (HA and NA) from A/SW/MN/02011/08 to generate the final 6+2 reassortant LAIV used 
for these studies.  
In experiment 1 (EXP1), (Figures 1, 3, 4, and 5) pigs were vaccinated intramuscularly 
with 2 mL of WIV (MN08) at 4 weeks and 7 weeks of age (4/7) or at 9 weeks and 12 weeks of 
age (9/12). Pigs in LAIV groups received 2 mL of LAIV (described above) at 106 50% tissue-
culture infectious dose (TCID50) per mL by intranasal inoculation at 4 weeks and 7 weeks of age. 
Pigs in the no adjuvant group were vaccinated intramuscularly with 2 mL of WIV (MN08) 
without adjuvant. A non-vaccinated (NV) group was included for controls. 
In experiment 2 (EXP2; Figure 2) pigs were vaccinated intramuscularly with 2 mL of a 
WIV MN08 at 4, 7 and 10 weeks of age. For LAIV vaccination 2 mL of a LAIV (as described 
above) at 106 TCID50 per mL was administered intranasally at 4 and 7 weeks of age. A non-
vaccinated (NV) group was included for controls. 
 Recall Antigens  
The MN08 (δ-cluster) virus, which was an identical match to the WIV vaccine and had 
matched surface genes to the LAIV vaccine, was used as homologous recall antigen. Pandemic 
A/CA/04/2009 (CA09, pH1N1) virus was used as heterologous recall antigen, which is an H1 
virus but in a different phylogenetic cluster. The A/turkey/Ohio/313053/04 (OH04, H3N2) virus 
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was used as heterosubtypic recall virus (different subtype than vaccine antigen), though the 
internal genes were a complete match to the internal genes of the LAIV and slightly different 
than the internal genes of the MN08 and CA09 viruses. All viruses were propagated in MDCK 
cells. MDCK cells were maintained in modified Eagle’s medium (MEM) and supplemented with 
antibiotics and 5% fetal bovine serum (FBS) (Atlanta Biologicals; Flowery Branch, GA). At the 
time of virus propagation, MDCK cells were cultured with Opti-MEM Reduced Serum Medium 
(Life Technologies; Grand Island, NY) and supplemented with antibiotics. Viruses were titered 
using traditional methods with MDCK cells and calculated using Reed and Muench [51]. For use 
as recall antigen, live viruses were diluted to 2.5 x 106/mL and 0.1 mL/well was used in assays 
described below.  
Peripheral blood mononuclear cell isolation 
To assess peripheral antigen-specific interferon-γ (IFN-γ) responses, whole blood was 
collected in sodium citrate CPT tubes (BD Vacutainer, Franklin Lakes, NJ) and peripheral blood 
mononuclear cells (PBMC) were separated according to the manufacturer’s recommendations at 
42, 45, and/or 77 days post-vaccination (dpv). PBMC were isolated as previously described 
(Loving et. al, 2012). Briefly, isolated PBMCs were washed with RPMI (Life Technologies; 
Grand Island, NY), filtered through a 40µm filter and washed once more. Cells were suspended 
in complete (c) RPMI (RPMI supplemented with 10% FCS, L-glutamine (Life Technologies; 
Grand Island, NY), 2-Mercaptoethanol (Sigma; St. Louis, MO), 25mM HEPES (Sigma; St. 
Louis, MO), essential amino acids and antibiotics (Sigma; St. Louis, MO.). PBMC were 
enumerated and seeded at 2.5 x 105 cells per well in both the ELISpot and ELISA. 
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Interferon-γ ELISpot assay 
The IFN-γ ELISpot assay was performed according to the manufacturer’s 
recommendations (porcine IFN-γ ELISpot assay; R& D Systems, Minneapolis, MN) as 
previously described [52]. Briefly, 50 µL of cRPMI was used to pre-wet ELISpot membrane. 
Cells were seeded in 0.1 mL and stimulated with 2.5 x 105 TCID50 of live MN08, CA09, or 
OH04, 0.25 µg of pokeweed mitogen (Sigma), or MDCK cell BSA-free media in 0.1 mL for a 
total of 0.25 mL per well. Following an 18 ± 1 h incubation in a 37ºC humidified 5% CO2 
incubator, the assay was completed according to manufacturer’s recommendations. Briefly, cells 
were removed, plates washed and incubated with secondary antibody and developed using HRP-
substrate provided by the manufactures. After membranes were dry, plates were scanned and 
analyzed with UV5-CTL ImmunoSpot instrumentation and software (Cellular Technology Ltd. 
Shaker Heights, OH) to count the number of spots per well. The mean spot count of duplicate 
wells for each treatment for each pig was determined and used to calculate differences between 
groups. 
Interferon-γ ELISA 
PBMC were plated in 96-well U-bottom plates (Corning Life Sciences, Tewksbury, MA) 
at 2.5 x 105 cells per well in 0.15 mL and stimulated as described for ELISpot (final volume 0.25 
mL). Cells were cultured for 72 ± 2 h and then supernatants were collected (pooled from 
duplicate treatment wells) and frozen at -80ºC until analysis. The IFN-γ ELISA assay was 
performed according to manufacturer’s recommendations (Porcine IFN-gamma DuoSet; R&D 
Systems, Minneapolis MN) and concentration calculated using recombinant protein standard. 
Plates were scanned and absorbency determined using SpectraMax M5 instrumentation 
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(Molecular Devices; Sunnyvale, CA) and data analyzed with SoftMax Pro 5 software (Molecular 
Devices; Sunnyvale, CA).   
Statistical Analysis  
ELISpot and ELISA data were analyzed using analysis of variance (ANOVA) with a P-
value of ≤ 0.05 considered to be significant (GraphPad Prism, GraphPad Software, La Jolla, 
CA). Responses considered to be significant based upon treatment group were analyzed using 
Tukey multicomparisons to determine the statistical difference between groups. 
Results 
Cellular immune responses following LAIV or WIV vaccination 
At 42 days post primary vaccination (dpv) IAV-specific T cell responses elicited in 
response to WIV and LAIV were evaluated using in vitro recall responses in the IFN-γ ELISpot 
and ELISA (Figure 1A). The number of IFN-γ secreting cells (SC) following stimulation with 
homologous (MN08, δ-cluster) and heterologous (CA09, pH1N1) viruses for pigs in the LAIV, 
WIV and NV vaccinated groups were determined. At 42 dpv the average number of SC in for the 
WIV group were statistically greater than responses elicited by the LAIV group (Fig.1A). Pigs in 
the NV group did not exhibit a detectable IFN-γ response to homologous or heterologous antigen 
stimulation (Figure 1A) when evaluated in the ELISpot assay. In general, IFN-γ responses as 
measured by ELISA were similar to those observed using ELISpot (Fig 1B).   
A separate study (EXP2) reiterated the significant increase in the number of peripheral 
IFN-γ SC to homologous virus (MN08) and heterologous virus (CA09) in the WIV group as 
compared to the LAIV group at 45 days post primary vaccination (Figure 2A). In this follow-up 
experiment the responses to homologous virus (MN08) were more prominent than responses to 
the heterologous virus (CA09) when evaluating the number of IFN-γ SC for the WIV group. 
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Similar results were observed when measuring IFN-γ in PBMC supernatants to both homologous 
and heterologous viruses (Figure 2B). However, in EXP1 (Figure 1B) there was no statistical 
difference in the amount of IFN-γ secreted following exposure to homologous virus as opposed 
to EXP2 (Figure 2B), in which a statistical difference in the number of IFN-γ SC in response to 
both homologous and heterologous virus were detected. In general, IFN-γ responses as measured 
by ELISA were similar to those observed using ELISpot (Fig 2B).   
There was a decline in average IFN-γ recall responses for WIV vaccinates overtime, as at 
42 dpv there were 71± 12 IFN-γ SC/ 2.5 x 105 PBMC (Figure 1A) and at 77 dpv there were 28 ± 
12 IFN-γ SC/ 2.5 x 105 PBMC (Figure 3A). For LAIV vaccinates, there was not statistical 
difference in IFN-γ recall responses over time as at 42 dpv there were 12 ± 6 IFN-γ SC/ 2.5 x 105 
PBMC (Figure 1A) and at 77 dpv there were 32 ± 15 IFN-γ SC/ 2.5 x 105 PBMC (Figure 3A). 
While recall responses following WIV vaccination decreased overtime, the recall response 
following LAIV vaccination remained steady over time, although it was significantly lower in 
relation to responses in WIV vaccinates. While there wasn’t a statistically significant increase in 
IFN-γ responses in the LAIV group between 42 to 77 dpv, there was a numerical trend in the 
increase of IFN-γ SC over time. 
In addition to the ELISpot, the ELISA was used to assess the quantity of IFN-γ secreted 
by PBMC following stimulation with recall antigen for 72 hours. Following stimulation with 
homologous virus (MN08), there was no statistical difference between responses elicited 
following WIV vaccination or LAIV vaccination; however, there was a statistical difference 
between vaccine groups when either CA09 or OH04 was used as recall antigen (Figure 1B). At 
77 dpv there was a statistical difference between the amount of IFN-γ produced by PBMC from 
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WIV vaccinates and NV group with CA09 or OH04 recall antigens, while there was no 
difference when the MN08 was used as recall antigen(Figure 3B).   
Impact of age on vaccination   
In order to assess the impact of age at the time of vaccination on subsequent IAV-specific 
IFN-γ responses, a study was completed in which pigs were vaccinated at 4 and 7 weeks of age 
(4/7) or 9 and 12 weeks of age (9/12) with WIV vaccine and peripheral IFN-γ responses were 
assessed 42 days post-priming. The number of IFN-γ SC cells was not statistically different 
when the homologous (MN08) recall antigen was used (Figure 4A). However, when 
heterologous virus (CA09) was used as the recall antigen   pigs vaccinated at 4 and 7 weeks of 
age had a significantly increased number of IFN-γ SC (76 ± 13 IFN-γ SC/2.5 x 105 PBMC) when 
compared to pigs vaccinated at 9 and 12 weeks of age (27 ± 6 IFN-γ SC/2.5 x 105 PBMC). 
PBMC from pigs in the NV group did not exhibit a detectable IFN-γ response following 
homologous or heterologous antigen stimulation. 
Similar results were observed with IFN-γ measured in PBMC supernatants using the 
ELISA. While there was not a significant difference in the amount of IFN-γ produced by PBMC 
from 4/7 and 9/12 vaccinates when using homologous virus(MN08) as recall antigen, there was a 
trend for increased responses in the 4/7 vaccinate group. However, when using either CA09 or 
OH04 as recall antigen, there was a significant increase in IFN-γ secreted by PBMC from pigs 
vaccinated at the younger age as compared to the older age. Following stimulation with 
heterologous CA09, PBMC from the 4/7 vaccinates secreted 6391 ±1337 pg/mL IFN-γ as 
compared to PBMC from the 9/12 vaccinates that secreted 857 ± 345 pg/mL IFN-γ. When 
heterosubtypic OH04 (H3N2) virus was used as recall antigen, PBMC from 4/7 vaccinates 
secreted 2634 ± 665 pg/mL IFN-γ, as compared to 992 ± 414 pg/mL IFN-γ from 9/12 vaccinates. 
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Impact of adjuvant 
For evaluation of IFN-γ recall responses following WIV vaccination up to this point, the 
WIV was formulated with an adjuvant. Thus, to evaluate the contribution of adjuvant to 
induction of IAV-specific IFN-γ responses, PBMC from pigs vaccinated at 4 and 7 weeks of age 
with WIV formulated with (WIV) or without adjuvant (No adjuvant) were collected and IFN-γ 
recall responses using ELISpot and ELISA were evaluated. At 42 dpv an average of 71 ± 12 
IFN-γ SC/2.5 x 105 PBMC were detected following adjuvanted WIV vaccination as compared to 
the group which received non-adjuvanted WIV vaccination (4± 3 IFN-γ SC/2.5 x 105 PBMC, 
when homologous  virus (MN08) was used as recall antigen (Figure 5A). Similar results were 
obtained when heterologous CA09 recall antigen was used, with 76 ± 13 IFN-γ SC/2.5 x 105 
PBMC detected for adjuvanted WIV group and 4 ± 2 IFN-γ SC/2.5 x 105 PBMC for non-
adjuvanted WIV group. Moreover, little to no IFN-γ was detected in supernatants of PBMC from 
pigs given non-adjuvanted WIV, which was similar to the response of non-vaccinated pigs. 
However, IFN-γ was produced by IAV-stimulated PBMC collected from adjuvanted WIV 
vaccinates (Figure 5B).  
Discussion 
 
Influenza A virus (IAV) vaccines for use in swine are available worldwide, however, due 
to antigenic drift and shift, as well as spillover events, vaccines currently licensed for use are 
providing limited protection and disease reduction. Live-attenuated influenza virus (LAIV) 
vaccines are not yet commercially available, however, have been shown to provide better cross-
protection in several studies [37, 38] Whole-inactivated virus (WIV) and LAIV platforms were 
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used to evaluate the induction of cell-mediated immunity following vaccination and compare the 
ability of IFN-γ ELISpot and ELISA to accurately assess antigen-specific recall responses. 
This study demonstrated that WIV vaccines, when formulated with adjuvant, induced a 
stronger peripheral cell-mediated IFN-γ response than the LAIV vaccines at 42 days post 
primary vaccination. This was observed in two independent experiments (Figures 1 and 2), and 
although there were subtle differences in the WIV vaccination regimen between experiment 1 
and 2 (Figures 1 and 2), the trends in responses between the vaccine groups were similar. The 
IAV-specific production of IFN-γ in WIV group after a tertiary vaccination (Figure 2) was 
increased in response to homologous virus when compared to the first experiment (Figure 1), 
however, the increase in the IFN-γ recall responses was not as dramatically increased following 
stimulation with homologous virus. PBMC were collected after the third dose of WIV was given, 
and a third dose of LAIV was not administered. These data suggest that the third boost increased 
responses to homologous, but not heterologous virus; thus, additional dosing with WIV did not 
induce cross-reactive IFN-γ responses and administration may not increase cross-protection.  
While the lack of a robust IAV-specific IFN-γ response following LAIV vaccination at 
42 days primary vaccination was somewhat unexpected, the IFN-γ recall responses was 
sustained in LAIV vaccinates but not WIV vaccinates. At 77 days post primary vaccination the 
number of IFN-γ SC from LAIV vaccinates was not different than the numbers at 42 dpv (Figure 
3A versus 1A). However, duration of CMI declined in the WIV vaccinated groups because IFN-γ 
SC were greater  for WIV vaccinates than for LAIV vaccinates, at 42 dpv (Figure 1A) when 
compared to  IFN-γ SC  for WIV vaccinates and  for LAIV vaccinates at 77 dpv (Figure 3A). 
This sustained IAV-specific IFN-γ response measured in the periphery following LAIV 
vaccination may be important in terms of duration of protection, though the response is quite low 
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in general. The decreased response in the WIV vaccinate group may be due to a waning effector 
T cell population and lack of an established peripheral memory T cell population. However, to 
make this conclusion further work would be needed to fully characterize the cell populations 
producing IFN-γ. Also, it would be interesting to delineate what T cell populations are producing 
IFN-γ at various time points following vaccination. 
Several previous studies have shown that LAIV vaccination generally elicits a stronger 
peripheral T cell response as measured by IFN-γ production [27, 38, 39, 53], when compared to 
other vaccine regimens, particularly WIV vaccines. Differences between study designs and 
vaccine formulations likely explain the differences between this study and other published 
reports. Specifically, in Loving et. al the WIV was formulated with only 8 HAU; however, in the 
data reported here the WIV vaccines were formulated at 128 HAU [27]. It has also, been 
observed that when the WIV is formulated at a HAU of 2 or less the peripheral IAV-specific 
IFN-γ response is severely dampened (unpublished results). In addition, the time between 
priming and boosting has been different between studies. The changes in vaccine regimen may 
alter subsequent immune responses, which may contribute to the levels of IFN-γ produced by 
PBMC post-vaccination. Another factor that may have impacted the response in the peripheral 
blood for LAIV in this study in comparison to other studies [27, 38, 39] is the number of cells 
used in the ELISpot was different amongst studies. In this study 2.5x 105 PBMC/well were used 
as compared to other studies which used 5x105 PBMC/well. 
The apparent lack of peripheral IFN-γ recall response in the LAIV group, may be the 
result of the site of immune induction, which is likely the respiratory mucosa as opposed to a 
peripheral lymph node. Thus, it is possible that given that LAIV has been shown to be more 
protective, IFN-γ producing IAV-specific T cells may be more measurable in the lung. Thus, in 
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the future it may be helpful to assess whether LAIV administration results in memory T cells at 
the site of vaccination.  
There was only a single instance when the conclusion on the differences in the peripheral 
IFN-γ recall response between WIV and LAIV vaccinates was different (Figure 1). Specifically, 
in the first experiment there was not a statistical difference between the amounts of IFN-γ 
secreted by PBMC from WIV vaccinates when compared to LAIV vaccinates (Fig. 1B). 
However, there was a difference in the number of IFN-γ SC for the same comparison. It is worth 
noting that the ELISpot does not quantify the amount of secreted IFN-γ, only the number of 
antigen-specific cells. While LAIV vaccinates may have fewer IFN-γ SC in the periphery, each 
cell may be producing more IFN-γ which could explain the difference sometimes observed 
between assays. However, in general, there was not major difference in the conclusions drawn 
when comparing the two recall assays. 
In addition to evaluating differences in IFN-γ recall responses between WIV and LAIV 
vaccinates, the impact of age at time of WIV vaccination was also assessed (Figure 4). Our data 
show that age at WIV vaccination had a significant impact on subsequent peripheral IFN-γ recall 
responses, regardless of assay used. There was a trend for increased number of IFN-γ SC and 
IFN-γ production following stimulation with homologous virus when vaccinated at 4/7 weeks of 
age in comparison to 9/12 weeks of age. However, recall responses were statistically affected by 
age at vaccination when evaluating recall responses to heterologous virus. These data clearly 
show a stronger peripheral IFN-γ responses when pigs receive WIV vaccine at a younger age. 
However, the induction peripheral IFN-γ recall responses required addition of adjuvant to the 
WIV antigen, as responses were completely lost when pigs were given WIV without adjuvant 
(Figure 5). While administration of WIV with adjuvant is necessary to induce a peripheral IFN-γ 
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response, the benefits of stronger response, as elicited following vaccination at 4/7 weeks of 
ages, remains to be determined.  
Results from other studies [7] emphasize that despite the critical role of IFN-γ in Th1 
mediated immunity, measurement of this cytokine alone is not sufficient as an immune correlate 
of protection for IAV. For future evaluation of WIV immunogenicity and protection it may be 
useful to assess additional T cell effector cytokines, such as IL-2, TNF-α, and IL-10, or other 
effector molecules such as perforin or granzyme to determine if there is a differential response 
for other cytokines that may be indicative of memory T cell populations or a more balanced 
immune response. T cells capable of producing multiple cytokines, including IFN-γ, TNF-α, and 
IL-2, correlated well with vaccine induced protection against chronic bacterial and viral 
infections compared to T cells producing only one cytokine at a time [7]. Vaccine potency can be 
influenced by the antigen dose and/or the adjuvant used [54] and may also affect the peripheral 
immune response following WIV vaccination. 
Overall, our data show that adjuvanted WIV vaccination elicits a more robust peripheral 
IFN-γ cell-mediated immune response than LAIV vaccination, but both age of WIV vaccination 
and formulation significantly impact WIV immunogenicity as it relates to peripheral IFN-γ 
responses. Evaluation of peripheral IFN-γ responses do not appear to be a useful measure of 
LAIV immunogenicity and would make a poor measure of vaccine efficacy. In general, 
conclusions of peripheral immunogenicity were similar regardless of the assay used to evaluate 
IFN-γ responses (ELISpot or ELISA). It is interesting to note that IFN-γ recall responses were 
similar regardless of the virus used as recall antigen (homologous or heterologous), suggesting 
that surface antigens may not be the primary antigen for peripheral T cell responses. While LAIV 
vaccines have been shown to be more cross-protective, peripheral immunogenicity is poor and 
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our data suggest that peripheral IFN-γ recall responses cannot be used a measure of LAIV 
immunogenicity nor protection. 
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CHAPTER 3: GENERAL CONCLUSIONS 
Influenza A viruses (IAV) evade established host immune mechanisms in two distinct 
ways: gradual antigenic drift of viral surface epitopes which allows escape from established 
serological immunity, and antigenic shift by the emergence of new viral strains arising from the 
reassortment of influenza virus RNA from different strains in a common host. Harnessing 
aspects of the immune response to offer protection against a broad range of circulating influenza 
strains and potentially an emergent pandemic strain would be a major advance.  
This thesis evaluated differential measures of peripheral IFN-γ recall responses to IAV 
antigen in swine following influenza vaccination. T cell responses can be readily measured in the 
IFN-γ recall assays used within the scope of this paper, following IAV vaccination, though 
several factors altered immunogenicity. The measurement of cytokines, such as IFN-γ, produced 
in response to recall antigen, may be useful in evaluating immunogenicity associated with WIV 
vaccines for influenza. However, for newer vaccine platforms delivered intranasally, peripheral 
recall responses may be a poor predictor of immunogenicity and vaccine efficacy.  
Understanding the correlates of protection associated with LAIV vaccines for influenza 
in swine remains limited. Current vaccines depend upon the use of killed viruses, which typically 
generate strain-specific protective antibody responses. LAIV vaccination may offer 
heterosubtypic protection, however, to date a LAIV has not been approved for the use in swine. 
Unlike antibody responses, cellular immune responses target viral proteins that are more likely to 
be shared between different IAV strains and subtypes [55, 56]. Thus, vaccine strategies targeting 
the internal proteins of influenza may be ideal to elicit a cellular immune response against a 
conserved set of IAV’s [57]. 
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LAIV vaccination strategies have been shown to induce protective cellular immune 
responses [5, 6, 35, 42]. Our data clearly show that if this is the case, the cells are not in 
peripheral circulation. In future studies aimed at identifying the mechanism of cross-protection 
elicited by LAIV vaccines, it would be advantageous to examine sites of induction of the 
immune response, including the lung and draining lymph nodes. Additionally, future studies 
evaluating T cell responses in the lung during and after IAV infection and LAIV vaccination 
would be very advantageous in understanding what factors are conveying protection for the host, 
and which of these responses are also elicited following LAIV vaccination. Future studies in 
which lung-resident or homing T cells are investigated directly by bronchial sampling techniques 
may offer insight into the relative contribution of CD4+ and CD8+ T cells in both orchestrating 
and effecting responses, and, subsequently, rational vaccine designs may be optimized. 
In future prospective studies when evaluating immune response to IAV in swine, further 
evaluation of other mechanistic actions may be necessary to fully discern the role of cell-
mediated immunity and help to identify a correlate of protection in IAV vaccination and 
infection .This may include further evaluation of T cell subsets including CD4+ T helper cells 
and CD8+ T cells.  CD4+ T helper cells arrive at the site of infection before CD8+ T cells, secrete 
IFN-γ and induce expression of chemokines to attract CD8+ T cells. CD4+ T helper cells 
therefore may respond in an antigen-specific manner and orchestrate the effector T cell response. 
However, they may also act directly as antiviral cytotoxic T cells, as they stain positive for 
perforin and granzyme and produce IFN-γ [42, 58]. This cytotoxic response at the site of 
infection may limit viral replication and disease severity. Thus, future studies entailing CD4+ T 
cells may be beneficial in obtaining a better understanding of host protection. 
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Lastly, generating broad memory responses, while establishing an appropriate pool of 
cells, such as CD4+ or CD4/CD8 double-positive cells, would be beneficial to the host. CD4+ T 
cell memory responses can recognize peptides from core viral proteins that are tightly conserved 
across strains, which may induce multiple, distinct memory subsets. LAIV vaccination induces a 
significantly larger number of effector T-cells than killed vaccines, ultimately giving rise to more 
memory cells [59]. Harnessing this response with appropriate technologies may provide an 
opportunity to produce inexpensive and effective vaccines with a broad spectrum of protection. 
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Figure 1 WIV vaccination elicits more peripheral IAV-specific IFN-γ secreting cells compared 
to LAIV vaccination. Pigs were vaccinated intramuscularly with WIV (MN08, δ-cluster) or 
intranasally with LAIV at 4 and 7 weeks of age. Peripheral blood mononuclear cells (PBMC) 
were collected at 42 days post initial vaccination for evaluation of IFN-γ recall responses 
(A)Number of IFN-γ secreting cells (SC) per 2.5 x 105 PBMC following stimulation with MN08 
(δ-cluster) or CA09 (pH1N1) virus determined by ELISpot. (B) Quantity of secreted IFN-γ 
protein measured in PBMC supernatants following stimulation with MN08 (δ-cluster), CA09 
(pH1N1), or OH04 (H3N2) determined by ELISA.  Each individual point represents the response 
of a single pig in the indicated group. Results are reported as mean ± standard error of mean 
(SEM), and statistical differences between groups are indicated with connecting bars (p ˂ 0.05).  
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Figure 2 After tertiary vaccination in WIV vaccination group more IAV-specific IFN-γ secreting 
cells are elicited as compared to LAIV vaccination at 45 days post initial vaccination.  PBMC 
were isolated from pigs vaccinated intramuscularly with 3 doses of WIV (MN08, δ-cluster) or 
two doses intranasally with LAIV for evaluation of IFN-γ recall responses (A) Number of IFN-γ 
secreting cells (SC) per 2.5 x 105 PBMC following stimulation with MN08 (δ-cluster) or CA09 
(pH1N1) virus determined by ELISpot. (B) Quantity of secreted IFN-γ protein measured in 
PBMC supernatants following stimulation with MN08 (δ-cluster) or CA09 (pH1N1) determined 
by ELISA.  Each individual point represents the response of a single pig in the indicated group. 
Results are reported as mean ± standard error of mean (SEM), and statistical differences between 
groups are indicated with connecting bars (p ˂ 0.05).  
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Figure 3 Peripheral IAV-specific IFN-γ responses decline in WIV vaccinated as responses 
increase in LAIV vaccinated. PBMC were collected at 77 days post-priming for evaluation of 
IFN-γ recall responses (A) Number of IFN-γ secreting cells (SC) in 2.5 x 105 PBMC following 
stimulation with MN08 (δ-cluster) or CA09 (pH1N1) virus was determined by ELISpot. (B) 
Quantity of secreted IFN-γ protein measured in PBMC supernatants following stimulation with 
MN08 (δ-cluster), CA09 (pH1N1), or OH04 (H3N2) determined by ELISA. Each individual 
point represents the response of a single pig in the indicated group. Results are reported as means 
± standard errors of means (SEM), and statistical differences between groups are indicated with 
connecting bars (p ˂ 0.05). 
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Figure 4 Age of WIV vaccination significantly impacts peripheral IAV-specific IFN-γ 
responses. PBMC were isolated from pigs vaccinated intramuscularly with adjuvanted WIV 
(MN08, δ-cluster) at 4 and 7 weeks of age (4/7) or 9 and 12 weeks of age (9/12) at 42 days post-
priming for evaluation of IFN-γ recall responses (A) Number of IFN-γ secreting cells (SC) in 2.5 
x 105 PBMC following stimulation with MN08 (δ-cluster) or CA09 (pH1N1) virus was 
determined by ELISpot. (B) Quantity of secreted IFN-γ protein was measured in PBMC 
supernatants following stimulation with MN08 (δ-cluster), CA09 (pH1N1), or OH04 (H3N2) 
determined by ELISA. Each individual point represents the response of a single pig in the 
indicated group. Results are reported as mean ± standard error of mean (SEM), and statistical 
differences between groups are indicated with connecting bars (p ˂ 0.05). 
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 Figure 5 Adjuvant with WIV is required to elicit a peripheral IAV-specific IFN-γ responses in 
pigs.  Pigs were vaccinated intramuscularly with WIV formulated with adjuvant or WIV without 
adjuvant (MN08, δ-cluster) at 4 and 7 weeks of age. PBMC were isolated from pigs vaccinated 
intramuscularly with WIV (MN08, δ-1 cluster) (A) Number of IFN-γ secreting cells (SC) in 2.5 
x 105 PBMC following stimulation with MN08 (δ-cluster) or CA09 (pH1N1) virus was 
determined by ELISpot. (B) Quantity of secreted IFN-γ protein was measured in PBMC 
supernatants following stimulation with MN08 (δ-cluster), CA09 (pH1N1), or OH04 (H3N2) 
determined by ELISA. Each individual point represents the response of a single pig in the 
indicated group.  Results are reported as mean ± standard error of mean (SEM), and statistical 
differences between groups are indicated with connecting bars (p ˂ 0.05) 
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